Mitotic kinesin inhibitors

A compound as illustrated by Formula II:

• wherein;
• a is 0 or 1;
• b is 0 or 1;
• m is 0, 1, or 2;
• r is 0 or 1;
• s is 0 or 1;
• R1 is selected from:
• 1) (C═O)C1-C10 alkyl;
• 6) (C═O)NRcRc′;
• 7) SO2NRcRc′;
• 8) SO2C1-C10 alkyl;
• said alkyl is optionally substituted with one or more substituents selected from R10;
• R2and R3 are H;
• R4, R5 and R9 are independently selected from:
• 1) H;
• 2) (C1-C10)alkyl;
• 3) (C1-C10)alkylamino;
• 4) (C1-C10)alkylhydroxy;
• R7 is H;
• R10 is:
• 1) (C═O)aObC1-C10 alkyl;
• 2) (C═O)aObaryl;
• 3) C2-C10 alkenyl;
• 4) C2-C10 alkynyl;
• 5) (C═O)aOb heterocyclyl;
• 6) CO2H;
• 7) halo;
• 8) CN;
• 9) OH;
• 10) ObC1-C6 perfluoroalkyl;
• 11) Oa(C═O)bNR11 R12;
• 12) S(O)mRa;
• 13) S(O)2NR11R12;
• 14) oxo;
• 15) CHO;
• 16) (N═O)R11R12;
• or
• 17) (C═O)aObC3-C8 cycloalkyl;
• said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R13;
• R10a and R10b are independently selected from:
• 1) H;
• 2) C1-C10 alkyl;
• 3) C2-C10 alkenyl;
• 4) C2-C10 alkynyl;
• 5) OH;
• 6) CN;
• 7) halo;
• 8) CHO;
• 9) CO2H;
• 10) (C1-C6)alkyl amino;
• and
• 11) (C1-C6)alkyl hydroxy;
• R11 and R12 are independently selected from:
• 1) H;
• 2) (C═O)ObC1-C10 alkyl;
• 3) (C═O)ObC3-C8 cycloalkyl;
• 4) (C═O)Obaryl;
• 5) (C═O)Obheterocyclyl;
• 6) C1-C10 alkyl;
• 7) aryl;
• 8) C2-C10 alkenyl;
• 9) C2-C10 alkynyl;
• 10) heterocyclyl;
• 11) C3-C8 cycloalkyl;
• 12) SO2Ra;
• 13) (C═O)NRb2;
• 14) oxo;
• and
• 15) OH;
• said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R13;
• or
• R11 and R12 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R13;
• R13 is selected from:
• 1) (C═O)rOs(C1-C10)alkyl;
• 2) Or(C1-C3)perfluoroalkyl;
• 3) (C0-C6)alkylene-S(O)mRa;
• 4) oxo;
• 5) OH;
• 6) halo;
• 7) CN;
• 8) (C═O)rOs(C2-C10)alkenyl;
• 9) (C═O)rOs(C2-C10)alkynyl;
• 10) (C═O)rOs(C3-C6)cycloalkyl;
• 11) (C═O)rOs(C0-C6)alkylene-aryl;
• 12) (C═O)rOs(C0-C6)alkylene-heterocyclyl;
• 13) (C═O)rOs(C0-C6)alkylene-N(Rb)2;
• 14) C(O)Ra;
• 15) (C0-C6)alkylene-CO2Ra;
• 16) C(O)H;
• 17) (C0-C6)alkylene-CO2H;
• 18) C(O)N(Rb)2;
• 19) S(O)mRa;
• and
• 20) S(O)2N(Rb)2;
• said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from Rb, OH, (C1-C6)alkoxy, halogen, CO2H, CN, O(C═O)C1-C6 alkyl, oxo, and N(Rb)2;
• Ra is (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, or heterocyclyl;
• said alkyl, cycloalkyl, aryl or heterocylyl is optionally substituted with one or more substituents selected from Rf,
• Rb is H, (C1-C6)alkyl, aryl, heterocyclyl, (C3-C6)cycloalkyl, (C═O)OC1-C6 alkyl, (C═O)C1-C6 alkyl or S(O)2Ra;
• said alkyl, cycloalkyl, aryl or heterocylyl is optionally substituted with one or more substituents selected from Rf,
• Rc and Rc′ are independently selected from:
• H, (C1-C6)alkyl, aryl, heterocyclyl and (C3-C6)cycloalkyl, optionally substituted with one, two or three substituents selected from R13, or
• Rc and Rc′ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 4-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R13;
• Re is selected from:
• H and (C1-C6)alkyl;
• and
• Rf is selected from:
• heterocyclyl, amino substituted heterocyclyl, (C1-C6)alkyl, amino (C1-C6)alkyl, (C1-C6)alkyl amino, hydroxy (C1-C6)alkyl, OH and NH2;
• or a pharmacuetically acceptable salt or stereoisomer thereof.